Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Aug 11, 2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile
Read more at globenewswire.com64.63
-0.19 (-0.29%)
Find more stocks in the Stock Screener
KYMR Latest News and Analysis
17 days ago - By: Chartmill
